EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy

Krishneel Prasad, Ryan S Cross, Misty R Jenkins iD

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Krishneel Prasad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Vic., Australia. Hauptthemen laut MEDLINE: Machine Learning, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic biology has made it possible to rewire natural cellular responses to treat disease, notably demonstrated by chimeric antigen receptor (CAR) T cells as cancer immunotherapy. Building on the success of T‐cell activation using synthetic receptors, the field is now investigating how induction of noncanonical signalling pathways and sophisticated synthetic gene circuitry can enhance the antitumour phenotype of engineered T cells. This commentary explores two recently published studies that provide proof of concept for how new technologies achieve this. The first demonstrated that non‐naturally occurring combinations of signalling motifs derived from various immune receptors and arranged as a CAR drove unique signal transduction pathways in T cells and improved their tumour killing ability. Here, machine learning complemented the screening process and successfully predicted CAR T‐cell phenotype dependent on signalling motif choice. The second explored how synthetic zinc fingers can be engineered into controllable transcriptional regulators, where their activity was dependent on the presence or absence of FDA‐approved small‐molecule drugs. These studies are pivotal in expanding the design choices available for gene circuits of the future and highlight how a single cellular therapy could respond to multiple environmental cues including target cell antigen expression, the tumour microenvironment composition and small molecule drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machine LearningReceptors, Chimeric AntigenImmunotherapy, AdoptiveNeoplasmsSynthetic BiologyGene Regulatory NetworksHumans

Stichwörter der Autor:innen

chimeric antigen receptor T cellsgene circuitsimmunotherapysignallingsynthetic biology

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Vic., Australia.
  • The Department of Medical Biology, The University of Melbourne, Parkville, Vic., Australia.
  • Department of Biochemistry and Chemistry, Institute for Molecular Science, La Trobe University, Bundoora, Vic., Australia.

ORCID-Profile: Misty R Jenkins

Förderung

  • NHMRC
  • National Health and Medical Research Council

Zitieren

APA

Prasad, K., Cross, R. S., & Jenkins, M. R. (2023). Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy. Molecular Oncology. https://doi.org/10.1002/1878-0261.13420

Vancouver

Prasad K, Cross RS, Jenkins MR. Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy. Molecular Oncology. 2023. doi:10.1002/1878-0261.13420

BibTeX
@article{Prasad2023,
  author = {Prasad, Krishneel and Cross, Ryan S and Jenkins, Misty R},
  title = {Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13420}
}
Kostenlos starten →